Clinical Trials
30 trialsNCT07570173 2026-05-26
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT06679829 2026-04-24
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05684692 2026-04-23
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Massachusetts General Hospital
Phase 2 Recruiting
NCT05316116 2026-02-05
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Terminated
NCT06470971 2026-01-20
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT03315026 2025-11-04
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04975555 2025-09-22
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
Phase 2 Active not recruiting
NCT04191421 2025-08-22
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Emory University
Phase 1/2 Completed
NCT07106671 2025-08-06
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06447376 2025-05-11
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT06352866 2025-03-03
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT05665725 2025-01-31
Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT05697510 2023-04-06
SILTUXILAM
Nantes University Hospital
Phase 1 Unknown
NCT01484275 2020-01-27
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT00401843 2019-11-19
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT01024036 2018-03-21
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
Janssen Research & Development, LLC
Phase 2 Completed
NCT02805868 2016-10-24
Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Northwestern University
Phase EARLY_PHASE1 Withdrawn
NCT01531998 2015-06-19
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01219010 2015-01-19
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT00911859 2014-11-18
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Janssen Research & Development, LLC
Phase 2 Completed
NCT00385827 2014-08-20
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Centocor, Inc.
Phase 2 Terminated
NCT00265135 2014-07-03
A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
Centocor, Inc.
Phase 1/2 Completed
NCT00412321 2014-07-01
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Centocor, Inc.
Phase 1 Completed
NCT00401765 2014-05-26
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Centocor, Inc.
Phase 1 Completed
NCT01309412 2014-05-19
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Terminated
NCT00402181 2014-05-14
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
Centocor, Inc.
Phase 2 Completed
NCT00841191 2014-05-14
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
Centocor, Inc.
Phase 1/2 Completed
NCT00311545 2013-02-20
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00433446 2013-02-05
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
SWOG Cancer Research Network
Phase 2 Completed
NCT01266811 2013-01-28
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Centocor, Inc.
Phase 3 Withdrawn